DPDermot Phelan

Dermot Phelan

*This is an algorithmically generated author record based on publicly available information.

Dermot Phelan has a total of 253 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Top Cited Papers

    Masters athletes with abnormal cardiovascular findings: a clinical consensus statement of the European Association of Preventive Cardiology of the ESC and the American College of Cardiology

    by Thijs M H Eijsvogels, Jonathan H Kim, Vincent L Aengevaeren, Flavio D’AScenzi, Tim W Churchill, Elizabeth H Dineen, María Sanz-De la Garza, Sabiha Gati, Geza Halasz, Kristina Haugaa, et al.

    Exercise training improves cardiovascular health and reduces the risk for future cardiovascular events and mortality. However, emerging evidence suggests that Masters athletes may have a higher prevalence of cardiovascular abnormalities, such as atrial arrhythmias, coronary atherosclerosis, aortic dilatation, and myocardial fibrosis, compared to their less active peers. The clinical management of Masters athletes may be challenging as available guidelines for such conditions are generally based on data derived from symptomatic sedentary patients, limiting their applicability to highly trained individuals. Other unique challenges in the clinical assessment of Masters athletes include differences in symptomatic presentations compared to sedentary individuals, potential resistance to the initiation of pharmacologic treatment, and the increasing availability of consumer wearable health data that may provide relevant information on their cardiovascular health status. The purpose of this joint EAPC/ESC and ACC Clinical Consensus Statement is to provide an in-depth update on the current state of knowledge on abnormal cardiovascular findings in Masters athletes. We present an expert-based approach on the diagnostic assessment, management, and prognosis of (i) atrial fibrillation, (ii) bradyarrhythmias, (iii) ventricular arrhythmias, (iv) coronary atherosclerosis, (v) aortic dilatation, (vi) myocardial fibrosis, and (vii) exercise-induced arrhythmogenic cardiomyopathy. Clinical challenges, areas of ongoing controversy, and uncertainty and the potential underlying mechanisms are discussed. We also present future perspectives and research directives to further refine current best practice strategies. This includes the need for clinical outcome studies, dedicated randomized controlled trials in athletes, and international registries with diverse populations and longitudinal follow-up to evaluate the natural history of cardiac abnormalities and facilitate development of evidence-based approaches in the clinical management of Masters athletes with cardiovascular abnormalities.


  • Open Access

    Incidence and Outcomes of Atrial Fibrillation and Systolic Dysfunction in Patients Receiving Mavacamten for Obstructive Hypertrophic Cardiomyopathy: A Multicenter Study

    by Olives Nguyen, Jack Wiedrick, Daniele Massera, Elizabeth Adlestein, Sumar Frejat, Matteo Castrichini, Said Alsidawi, John R. Giudicessi, Jeffrey B. Geske, Richard T. Carrick, et al.

    Importance Mavacamten is highly effective in treating symptomatic obstructive hypertrophic cardiomyopathy (oHCM) and was approved for commercial use with a risk mitigation program (REMS) to monitor the impact on left ventricular systolic function (LVSD). The impact of mavacamten on atrial fibrillation (AF) occurrence is not well characterized. Objective Determine the real-world incidence of new-onset and recurrent AF among patients with HCM treated with commercial mavacamten. Secondary objectives included assessing the incidences of LVSD, heart failure (HF), and cardiogenic shock. Design A multicenter cohort study. Center-level data were aggregated for patients who received mavacamten from May 2022 through December 2024. Setting Twenty-one outpatient HCM centers in the United States. Participants Consecutive patients ≥18 years of age with oHCM were included; those with permanent AF were excluded. Exposures At least one dose of commercial mavacamten. Main Outcomes and Measures Incidence of new-onset and recurrent AF, LVSD, HF, and cardiogenic shock. Results Among 1,538 patients (median age, 66 years [95% CI, 65.9–66.1]; 57% female [95% CI, 54–59%]), 25% [95% CI, 22-27%] had prior AF. Median mavacamten exposure was 13.4 months [95% CI, 11.8–15.0]. Overall AF incidence was 13% [95% CI, 10–17%], including 5% [95% CI, 4–7%] new-onset and 39% [95% CI, 27–51%] recurrent AF in those with history of AF prior to mavacamten initiation. LVEF Conclusions and Relevance In this multicenter cohort receiving commercial mavacamten, we identified an annual incidence of 5% new-onset AF and 39% recurrent AF, while 70% of patients who developed LVEFQuestion What are the real-world burden and consequences of atrial fibrillation (AF) in patients with hypertrophic cardiomyopathy treated with commercial mavacamten? Findings In a multicenter cohort of more than 1,500 patients, 5% experienced new-onset AF, while 39% of those with pre-existing AF experienced recurrence after mavacamten initiation. Left ventricular ejection fraction (LVEF) fell below 50% in 8% of patients, 70% of whom had concurrent AF. Meaning Real-world experience with mavacamten emphasizes that regular surveillance for AF is an important aspect of managing patients with HCM. Additionally, the identification of AF should prompt LVEF assessment and aggressive rhythm management, given the potential association between AF and decrease in LVEF. The observed incidence of AF on mavacamten highlights the need for further studies on potential mechanisms and for proactive surveillance and management strategies.


  • Open Access

    The Hidden Benefits of Septal Myectomy

    by Dermot Phelan, John Symanski

  • A Practical Approach to Echocardiographic Imaging in Patients With Hypertrophic Cardiomyopathy

    by Carol C. Mitchell, Cody Frye, Madeline Jankowski, John Symanski, Steven J. Lester, Anna Woo, Yvonne Gilliland, Andreea Dragulescu, Theodore Abraham, Milind Desai, et al.


  • Does cardiovascular preparticipation screening cause psychological distress in athletes? A systematic review

    by Braeden Hill, Nicholas Grubic, Matthew Williamson, Dermot M Phelan, Aaron L Baggish, Paul Dorian, Jonathan A Drezner, Amer M Johri

    Objective To evaluate the psychological implications of cardiovascular preparticipation screening (PPS) in athletes. Design Systematic review. Data sources MEDLINE, EMBASE, PubMed, CINAHL, SPORTDiscus, APA PsycInfo, Cochrane Library and grey literature sources. Study eligibility criteria Observational and experimental studies assessing a population of athletes who participated in a cardiovascular PPS protocol, where psychological outcomes before, during and/or after PPS were reported. Methods Results of included studies were synthesised by consolidating similar study-reported measures for key psychological outcomes before, during and/or after screening. Summary measures (medians, ranges) were computed across studies for each psychological outcome. Results A total of eight studies were included in this review (median sample size: 479). Study cohorts consisted of high school, collegiate, professional and recreational athletes (medians: 59% male, 20.5 years). Most athletes reported positive reactions to screening and would recommend it to others (range 88%–100%, five studies). Increased psychological distress was mainly reported among athletes detected with pathological cardiac conditions and true-positive screening results. In comparison, athletes with false-positive screening results still reported an increased feeling of safety while participating in sport and were satisfied with PPS. A universal conclusion across all studies was that most athletes did not experience psychological distress before, during or after PPS, regardless of the screening modality used or accuracy of results. Conclusion Psychological distress associated with PPS in athletes is rare and limited to athletes with true-positive findings. To mitigate downstream consequences in athletes who experience psychological distress, appropriate interventions and resources should be accessible prior to the screening procedure. PROSPERO registration number CRD42021272887.


  • Top Cited Papers
    Open Access

    Wearable Sensor Technology to Predict Core Body Temperature: A Systematic Review

    by Conor M. Dolson, Ethan R. Harlow, Dermot M. Phelan, Tim J. Gabbett, Benjamin Gaal, Christopher McMellen, Benjamin J. Geletka, Jacob G. Calcei, James E. Voos, Dhruv R. Seshadri

    Heat-related illnesses, which range from heat exhaustion to heatstroke, affect thousands of individuals worldwide every year and are characterized by extreme hyperthermia with the core body temperature (CBT) usually > 40 °C, decline in physical and athletic performance, CNS dysfunction, and, eventually, multiorgan failure. The measurement of CBT has been shown to predict heat-related illness and its severity, but the current measurement methods are not practical for use in high acuity and high motion settings due to their invasive and obstructive nature or excessive costs. Noninvasive predictions of CBT using wearable technology and predictive algorithms offer the potential for continuous CBT monitoring and early intervention to prevent HRI in athletic, military, and intense work environments. Thus far, there has been a lack of peer-reviewed literature assessing the efficacy of wearable devices and predictive analytics to predict CBT to mitigate heat-related illness. This systematic review identified 20 studies representing a total of 25 distinct algorithms to predict the core body temperature using wearable technology. While a high accuracy in prediction was noted, with 17 out of 18 algorithms meeting the clinical validity standards. few algorithms incorporated individual and environmental data into their core body temperature prediction algorithms, despite the known impact of individual health and situational and environmental factors on CBT. Robust machine learning methods offer the ability to develop more accurate, reliable, and personalized CBT prediction algorithms using wearable devices by including additional data on user characteristics, workout intensity, and the surrounding environment. The integration and interoperability of CBT prediction algorithms with existing heat-related illness prevention and treatment tools, including heat indices such as the WBGT, athlete management systems, and electronic medical records, will further prevent HRI and increase the availability and speed of data access during critical heat events, improving the clinical decision-making process for athletic trainers and physicians, sports scientists, employers, and military officers.


  • When to consider cardiac MRI in the evaluation of the competitive athlete after SARS-CoV-2 infection

    by Dermot Phelan, Jonathan H Kim, Jonathan A Drezner, Michael D Elliott, Matthew W Martinez, Eugene H Chung, Sheela Krishan, Benjamin D Levine, Aaron L Baggish


  • Point-of-Care Ultrasonography

    by Dermot M Phelan, Susan A Mayer, Raymond F Stainback

    To the Editor: On behalf of the American Society of Echocardiography (ASE), we wish to add points of emphasis and clarification to the excellent review article by Díaz-Gómez et al. (Oct. 21 issue)1 on point-of-care ultrasonography (POCUS). The express mission of the ASE is to educate and support all users of cardiac ultrasonography. Cardiac POCUS, a versatile tool, provides rapid bedside diagnosis when used by adequately trained professionals. However, substantial harm can be inflicted by unqualified users who may miss or misinterpret data, which can lead to the withholding of lifesaving therapies or the initiation of inappropriate treatments. Cardiac POCUS . . .


  • Bystander interventions and survival after exercise-related sudden cardiac arrest: a systematic review

    by Nicholas Grubic, Braeden Hill, Dermot Phelan, Aaron Baggish, Paul Dorian, Amer M Johri

    Objective To evaluate the provision of bystander interventions and rates of survival after exercise-related sudden cardiac arrest (SCA). Design Systematic review. Data sources MEDLINE, EMBASE, PubMed, CINAHL, SPORTDiscus, Cochrane Library and grey literature sources were searched from inception to November/December 2020. Study eligibility criteria Observational studies assessing a population of exercise-related SCA (out-of-hospital cardiac arrests that occurred during exercise or within 1 hour of cessation of activity), where bystander cardiopulmonary resuscitation (CPR) and/or automated external defibrillator (AED) use were reported, and survival outcomes were ascertained. Methods Among all included studies, the median (IQR) proportions of bystander CPR and bystander AED use, as well as median (IQR) rate of survival to hospital discharge, were calculated. Results A total of 29 studies were included in this review, with a median study duration of 78.7 months and a median sample size of 91. Most exercise-related SCA patients were male (median: 92%, IQR: 86%–96%), middle-aged (median: 51, IQR: 39–56 years), and presented with a shockable arrest rhythm (median: 78%, IQR: 62%–86%). Bystander CPR was initiated in a median of 71% (IQR: 59%–87%) of arrests, whereas bystander AED use occurred in a median of 31% (IQR: 19%–42%) of arrests. Among the 19 studies that reported survival to hospital discharge, the median rate of survival was 32% (IQR: 24%–49%). Studies which evaluated the relationship between bystander interventions and survival outcomes reported that both bystander CPR and AED use were associated with survival after exercise-related SCA. Conclusion Exercise-related SCA occurs predominantly in males and presents with a shockable ventricular arrhythmia in most cases, emphasising the importance of rapid access to defibrillation. Further efforts are needed to promote early recognition and a rapid bystander response to exercise-related SCA.


  • Prognostication in Cardiac Amyloidosis

    by Dermot Phelan, Jai Singh